<p>Bicycle Therapeutics plc (NASDAQ:BCYC - 获取免费报告) 的股价在周一的午盘交易中达到了新的 52 周低点。该公司的股价最低为 8.25 美元，最后交易价格为 8.64 美元，交易量为 418 股。该股票之前的收盘价为 8.97 美元。</p>
<p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 BCYC 进行了评论。Stephens 重申了 “持平” 的评级，并在 1 月 22 日的研究报告中将 Bicycle Therapeutics 的目标价设定为 15.00 美元。HC Wainwright 重申了 “买入” 评级，并在 2 月 26 日的研究报告中将 Bicycle Therapeutics 的目标价设定为 33.00 美元。JMP Securities 将 Bicycle Therapeutics 的目标价从 32.00 美元下调至 26.00 美元，并在 12 月 18 日的研究报告中为该公司设定了 “市场表现优于大盘” 的评级。Needham &amp; Company LLC 在 3 月 11 日的研究报告中重申了 “买入” 评级，并将 Bicycle Therapeutics 的目标价设定为 30.00 美元。最后，B. Riley 将 Bicycle Therapeutics 的目标价从 28.00 美元下调至 17.00 美元，并在 12 月 13 日的研究报告中为该公司设定了 “中性” 评级。两位研究分析师对该股票给予了持有评级，六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，Bicycle Therapeutics 目前的平均评级为 “适度买入”，平均目标价为 29.14 美元。</p>
<p><strong>获取我们关于 BCYC 的最新研究报告</strong></p>
<h2>Bicycle Therapeutics 股价下跌 6.1%</h2>
<p>该公司的 50 日移动平均价格为 11.32 美元，200 日移动平均价格为 17.52 美元。该股票的市值为 5.8289 亿美元，市盈率为-2.57，贝塔值为 1.12。</p>
<p>Bicycle Therapeutics (NASDAQ:BCYC - 获取免费报告) 最近在 2 月 25 日发布了季度收益数据。该公司报告季度每股收益为 (-0.75) 美元，超出分析师共识预期的 (-0.85) 美元 0.10 美元。该公司在季度内的收入为 370 万美元，而分析师预期为 547 万美元。Bicycle Therapeutics 的净利润率为-450.64%，股本回报率为-27.35%。该公司的收入同比下降了 30.2%。去年同期，该公司每股收益为 (-1.16) 美元。平均而言，卖方分析师预测 Bicycle Therapeutics plc 在当前财年将发布-3.06 美元的每股收益。</p>
<h2>Bicycle Therapeutics 的内部交易</h2>
<p>在相关消息中，首席会计官 Travis Alvin Thompson 在 1 月 6 日的交易中出售了 2,686 股公司的股票。这些股票以平均价格 15.00 美元出售，总价值为 40,290.00 美元。交易完成后，首席会计官现在持有 32,146 股公司股票，价值 482,190 美元。此次交易使其持股减少了 7.71%。该出售在向 SEC 的备案中披露，相关信息可在 SEC 网站上找到。此外，首席执行官 Kevin Lee 在 1 月 2 日的交易中出售了 9,038 股股票。这些股票以平均价格 14.09 美元出售，总价值为 127,345.42 美元。出售后，首席执行官现在直接持有 495,026 股公司股票，价值 6,974,916.34 美元。此次交易使其持股减少了 1.79%。该出售的披露信息可以在此找到。在过去的 90 天内，内部人士出售了 27,677 股公司股票，价值 392,413 美元。当前 8.50% 的股票由内部人士持有。</p>
<h2>机构投资者对 Bicycle Therapeutics 的看法</h2>
<p>对冲基金最近对该股票的持仓进行了调整。巴克莱银行在第四季度将其在 Bicycle Therapeutics 的持仓增加了 878.3%。巴克莱银行现在持有 2,612 股公司股票，价值 37,000 美元，此前在上个季度购买了 2,345 股。Avior Wealth Management LLC 在第四季度收购了 Bicycle Therapeutics 的新股份，估计价值约为 57,000 美元。摩根大通在第三季度将其在 Bicycle Therapeutics 的持仓增加了 26.8%。摩根大通现在持有 8,424 股公司股票，价值 191,000 美元，此前在上个季度购买了 1,782 股。中国泛华资产管理有限公司在第四季度将其在 Bicycle Therapeutics 的持仓增加了 30.7%。中国泛华资产管理有限公司现在持有 9,329 股公司股票，价值 131,000 美元，此前在上个季度购买了 2,191 股。最后，Erste Asset Management GmbH 在第三季度购买了 Bicycle Therapeutics 的新股份，估计价值为 325,000 美元。当前 86.15% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Bicycle Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 期临床试验的自行车毒素结合物（BTC），用于治疗高 Nectin-4 表达肿瘤；BT5528，一种正在进行 I/II 期临床试验的 BTC，用于治疗 Ephrin A 型受体 2 表达肿瘤；BT7480，一种正在进行 I/II 期临床试验的自行车 TICA 分子，针对 Nectin-4 并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的自行车 TICA 分子，目前处于临床前试验阶段。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Bicycle Therapeutics 更好</li>
<li>FTSE 100 指数是什么？</li>
<li>AT&amp;T 和 Verizon：两个电信巨头的免税投资</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>3 只高表现科技 ETF 以多样化您的投资组合</li>
<li>为什么投资高收益股息股票？</li>
<li>Netflix 作为安全避风港股票有望大幅反弹</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Bicycle Therapeutics 吗？</h2>
<p>在考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Bicycle Therapeutics 并不在名单上。</p>
<p>虽然 Bicycle Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BCYC

<p>Bicycle Therapeutics（纳斯达克代码：BCYC）股价创下 52 周新低，报 8.25 美元，收盘价为 8.64 美元。分析师的评级不一，目标价范围在 15 美元到 33 美元之间。该公司报告的季度每股收益为（0.75 美元），超出预期，但营收为 370 万美元，未达到预期。内部人士进行了股票出售，执行官们出售了大量股份。对冲基金也调整了其持仓，巴克莱银行将其持股增加了 878.3%。该股票的市值为 5.8289 亿美元，净利润率为负 450.64%</p>

<p>Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $8.25 and last traded at $8.64, with a volume of 418 shares trading hands. The stock had previously closed at $8.97.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc (NASDAQ:BCYC - 获取免费报告) 的股价在周一的午盘交易中达到了新的 52 周低点。该公司的股价最低为 8.25 美元，最后交易价格为 8.64 美元，交易量为 418 股。该股票之前的收盘价为 8.97 美元。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms have recently commented on BCYC. Stephens reaffirmed an &#34;equal weight&#34; rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. JMP Securities cut their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a &#34;market outperform&#34; rating for the company in a research report on Wednesday, December 18th. Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research note on Tuesday, March 11th. Finally, B. Riley reduced their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a &#34;neutral&#34; rating for the company in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $29.14.</p>
<div class="lb-trans"><p>几家研究公司最近对 BCYC 进行了评论。Stephens 重申了 “持平” 的评级，并在 1 月 22 日的研究报告中将 Bicycle Therapeutics 的目标价设定为 15.00 美元。HC Wainwright 重申了 “买入” 评级，并在 2 月 26 日的研究报告中将 Bicycle Therapeutics 的目标价设定为 33.00 美元。JMP Securities 将 Bicycle Therapeutics 的目标价从 32.00 美元下调至 26.00 美元，并在 12 月 18 日的研究报告中为该公司设定了 “市场表现优于大盘” 的评级。Needham &amp; Company LLC 在 3 月 11 日的研究报告中重申了 “买入” 评级，并将 Bicycle Therapeutics 的目标价设定为 30.00 美元。最后，B. Riley 将 Bicycle Therapeutics 的目标价从 28.00 美元下调至 17.00 美元，并在 12 月 13 日的研究报告中为该公司设定了 “中性” 评级。两位研究分析师对该股票给予了持有评级，六位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，Bicycle Therapeutics 目前的平均评级为 “适度买入”，平均目标价为 29.14 美元。</p>
</div><p><strong>Get Our Latest Research Report on BCYC</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 BCYC 的最新研究报告</strong></p>
</div><h2>Bicycle Therapeutics Trading Down 6.1 %</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股价下跌 6.1%</h2>
</div><p>The business has a 50-day moving average price of $11.32 and a 200 day moving average price of $17.52. The stock has a market capitalization of $582.89 million, a P/E ratio of -2.57 and a beta of 1.12.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 11.32 美元，200 日移动平均价格为 17.52 美元。该股票的市值为 5.8289 亿美元，市盈率为-2.57，贝塔值为 1.12。</p>
</div><p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analysts' expectations of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business's revenue was down 30.2% on a year-over-year basis. During the same period last year, the company posted ($1.16) EPS. On average, sell-side analysts predict that Bicycle Therapeutics plc will post -3.06 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Bicycle Therapeutics (NASDAQ:BCYC - 获取免费报告) 最近在 2 月 25 日发布了季度收益数据。该公司报告季度每股收益为 (-0.75) 美元，超出分析师共识预期的 (-0.85) 美元 0.10 美元。该公司在季度内的收入为 370 万美元，而分析师预期为 547 万美元。Bicycle Therapeutics 的净利润率为-450.64%，股本回报率为-27.35%。该公司的收入同比下降了 30.2%。去年同期，该公司每股收益为 (-1.16) 美元。平均而言，卖方分析师预测 Bicycle Therapeutics plc 在当前财年将发布-3.06 美元的每股收益。</p>
</div><h2>Insider Transactions at Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 的内部交易</h2>
</div><p>In related news, CAO Travis Alvin Thompson sold 2,686 shares of the business's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the transaction, the chief accounting officer now owns 32,146 shares of the company's stock, valued at $482,190. The trade was a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin Lee sold 9,038 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $127,345.42. Following the sale, the chief executive officer now directly owns 495,026 shares in the company, valued at $6,974,916.34. This trade represents a 1.79 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席会计官 Travis Alvin Thompson 在 1 月 6 日的交易中出售了 2,686 股公司的股票。这些股票以平均价格 15.00 美元出售，总价值为 40,290.00 美元。交易完成后，首席会计官现在持有 32,146 股公司股票，价值 482,190 美元。此次交易使其持股减少了 7.71%。该出售在向 SEC 的备案中披露，相关信息可在 SEC 网站上找到。此外，首席执行官 Kevin Lee 在 1 月 2 日的交易中出售了 9,038 股股票。这些股票以平均价格 14.09 美元出售，总价值为 127,345.42 美元。出售后，首席执行官现在直接持有 495,026 股公司股票，价值 6,974,916.34 美元。此次交易使其持股减少了 1.79%。该出售的披露信息可以在此找到。在过去的 90 天内，内部人士出售了 27,677 股公司股票，价值 392,413 美元。当前 8.50% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Bicycle Therapeutics 的看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its position in shares of Bicycle Therapeutics by 878.3% in the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at approximately $57,000. JPMorgan Chase &amp; Co. grew its holdings in Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase &amp; Co. now owns 8,424 shares of the company's stock worth $191,000 after purchasing an additional 1,782 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Bicycle Therapeutics by 30.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after purchasing an additional 2,191 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Bicycle Therapeutics during the 3rd quarter valued at $325,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近对该股票的持仓进行了调整。巴克莱银行在第四季度将其在 Bicycle Therapeutics 的持仓增加了 878.3%。巴克莱银行现在持有 2,612 股公司股票，价值 37,000 美元，此前在上个季度购买了 2,345 股。Avior Wealth Management LLC 在第四季度收购了 Bicycle Therapeutics 的新股份，估计价值约为 57,000 美元。摩根大通在第三季度将其在 Bicycle Therapeutics 的持仓增加了 26.8%。摩根大通现在持有 8,424 股公司股票，价值 191,000 美元，此前在上个季度购买了 1,782 股。中国泛华资产管理有限公司在第四季度将其在 Bicycle Therapeutics 的持仓增加了 30.7%。中国泛华资产管理有限公司现在持有 9,329 股公司股票，价值 131,000 美元，此前在上个季度购买了 2,191 股。最后，Erste Asset Management GmbH 在第三季度购买了 Bicycle Therapeutics 的新股份，估计价值为 325,000 美元。当前 86.15% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>关于 Bicycle Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 期临床试验的自行车毒素结合物（BTC），用于治疗高 Nectin-4 表达肿瘤；BT5528，一种正在进行 I/II 期临床试验的 BTC，用于治疗 Ephrin A 型受体 2 表达肿瘤；BT7480，一种正在进行 I/II 期临床试验的自行车 TICA 分子，针对 Nectin-4 并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的自行车 TICA 分子，目前处于临床前试验阶段。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>What is the FTSE 100 index?</li>
<li>AT&amp;T and Verizon: 2 Telecom Titans for a Tariff-Proof Play</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>3 High-Performing Tech ETFs to Diversify Your Portfolio</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Netflix Poised for Significant Rally as a Safe Haven Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Bicycle Therapeutics 更好</li>
<li>FTSE 100 指数是什么？</li>
<li>AT&amp;T 和 Verizon：两个电信巨头的免税投资</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>3 只高表现科技 ETF 以多样化您的投资组合</li>
<li>为什么投资高收益股息股票？</li>
<li>Netflix 作为安全避风港股票有望大幅反弹</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bicycle Therapeutics 吗？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Bicycle Therapeutics 并不在名单上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bicycle Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bicycle Therapeutics（纳斯达克股票代码：BCYC）创下新的 12 个月低点 - 你应该卖出吗？